Waters Corporation (0LTI.L)
USD 325.39
(-5.2%)
USD 325.39
(-5.2%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 516.23 Million USD | 13.28% |
| 2022 | 455.71 Million USD | 27.97% |
| 2021 | 356.09 Million USD | 17.03% |
| 2020 | 304.28 Million USD | -5.08% |
| 2019 | 320.55 Million USD | 9.94% |
| 2018 | 291.56 Million USD | 7.87% |
| 2017 | 270.29 Million USD | 2.9% |
| 2016 | 262.68 Million USD | -0.28% |
| 2015 | 263.41 Million USD | 6.89% |
| 2014 | 246.43 Million USD | 1.5% |
| 2013 | 242.8 Million USD | 5.77% |
| 2012 | 229.56 Million USD | 7.85% |
| 2011 | 212.86 Million USD | 4.19% |
| 2010 | 204.3 Million USD | 14.35% |
| 2009 | 178.66 Million USD | 3.24% |
| 2008 | 173.05 Million USD | -1.61% |
| 2007 | 175.88 Million USD | 4.42% |
| 2006 | 168.43 Million USD | 28.04% |
| 2005 | 131.55 Million USD | -5.97% |
| 2004 | 139.9 Million USD | 8.61% |
| 2003 | 128.81 Million USD | 15.47% |
| 2002 | 111.55 Million USD | 8.61% |
| 2001 | 102.71 Million USD | 17.69% |
| 2000 | 87.27 Million USD | 8.55% |
| 1999 | 80.4 Million USD | 0.12% |
| 1998 | 80.3 Million USD | -8.12% |
| 1997 | 87.4 Million USD | 84.39% |
| 1996 | 47.4 Million USD | 14.22% |
| 1995 | 41.5 Million USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q3 | 518.99 Million USD | -0.75% |
| 2024 Q2 | 522.92 Million USD | -2.92% |
| 2024 Q1 | 538.63 Million USD | 4.34% |
| 2023 Q4 | 516.23 Million USD | -5.17% |
| 2023 Q2 | 536.82 Million USD | 7.49% |
| 2023 FY | 516.23 Million USD | 13.28% |
| 2023 Q1 | 499.42 Million USD | 9.59% |
| 2023 Q3 | 544.4 Million USD | 1.41% |
| 2022 Q1 | 381.9 Million USD | 7.25% |
| 2022 FY | 455.71 Million USD | 27.97% |
| 2022 Q4 | 455.71 Million USD | 3.05% |
| 2022 Q3 | 442.23 Million USD | 7.88% |
| 2022 Q2 | 409.92 Million USD | 7.34% |
| 2021 FY | 356.09 Million USD | 17.03% |
| 2021 Q1 | 327.96 Million USD | 7.78% |
| 2021 Q4 | 356.09 Million USD | -8.4% |
| 2021 Q2 | 348.77 Million USD | 6.34% |
| 2021 Q3 | 388.75 Million USD | 11.46% |
| 2020 Q3 | 326.94 Million USD | -4.96% |
| 2020 Q4 | 304.28 Million USD | -6.93% |
| 2020 FY | 304.28 Million USD | -5.08% |
| 2020 Q1 | 344 Million USD | 7.32% |
| 2020 Q2 | 344 Million USD | 0.0% |
| 2019 FY | 320.55 Million USD | 9.94% |
| 2019 Q4 | 320.55 Million USD | -13.08% |
| 2019 Q1 | 333.3 Million USD | 14.32% |
| 2019 Q3 | 368.79 Million USD | 4.9% |
| 2019 Q2 | 351.55 Million USD | 5.47% |
| 2018 Q3 | 313.61 Million USD | 4.68% |
| 2018 Q1 | 299.61 Million USD | 10.85% |
| 2018 Q4 | 291.56 Million USD | -7.03% |
| 2018 FY | 291.56 Million USD | 7.87% |
| 2018 Q2 | 299.59 Million USD | -0.01% |
| 2017 Q1 | 279.97 Million USD | 6.58% |
| 2017 Q4 | 270.29 Million USD | -9.25% |
| 2017 Q3 | 297.85 Million USD | 3.73% |
| 2017 Q2 | 287.13 Million USD | 2.56% |
| 2017 FY | 270.29 Million USD | 2.9% |
| 2016 Q2 | 286.44 Million USD | -0.21% |
| 2016 FY | 262.68 Million USD | -0.28% |
| 2016 Q4 | 262.68 Million USD | -13.36% |
| 2016 Q3 | 303.18 Million USD | 5.84% |
| 2016 Q1 | 287.04 Million USD | 8.97% |
| 2015 Q3 | 281.78 Million USD | 3.24% |
| 2015 Q4 | 263.41 Million USD | -6.52% |
| 2015 Q1 | 257.53 Million USD | 4.5% |
| 2015 Q2 | 272.93 Million USD | 5.98% |
| 2015 FY | 263.41 Million USD | 6.89% |
| 2014 Q4 | 246.43 Million USD | -8.42% |
| 2014 Q1 | 266.62 Million USD | 9.81% |
| 2014 Q2 | 272.76 Million USD | 2.3% |
| 2014 Q3 | 269.09 Million USD | -1.35% |
| 2014 FY | 246.43 Million USD | 1.5% |
| 2013 Q2 | 242.64 Million USD | 2.86% |
| 2013 FY | 242.8 Million USD | 5.77% |
| 2013 Q4 | 242.8 Million USD | -5.52% |
| 2013 Q3 | 256.98 Million USD | 5.91% |
| 2013 Q1 | 235.88 Million USD | 2.75% |
| 2012 Q1 | 233.36 Million USD | 9.63% |
| 2012 Q2 | 236.76 Million USD | 1.46% |
| 2012 Q3 | 246.99 Million USD | 4.32% |
| 2012 Q4 | 229.56 Million USD | -7.06% |
| 2012 FY | 229.56 Million USD | 7.85% |
| 2011 Q2 | 243.18 Million USD | 8.62% |
| 2011 FY | 212.86 Million USD | 4.19% |
| 2011 Q1 | 223.88 Million USD | 9.58% |
| 2011 Q3 | 246.25 Million USD | 1.27% |
| 2011 Q4 | 212.86 Million USD | -13.56% |
| 2010 Q1 | 189.22 Million USD | 5.91% |
| 2010 FY | 204.3 Million USD | 14.35% |
| 2010 Q4 | 204.3 Million USD | -1.94% |
| 2010 Q3 | 208.33 Million USD | 8.63% |
| 2010 Q2 | 191.78 Million USD | 1.35% |
| 2009 Q2 | 196.31 Million USD | 2.82% |
| 2009 FY | 178.66 Million USD | 3.24% |
| 2009 Q4 | 178.66 Million USD | -9.35% |
| 2009 Q3 | 197.08 Million USD | 0.39% |
| 2009 Q1 | 190.92 Million USD | 10.33% |
| 2008 Q2 | 206.87 Million USD | 5.1% |
| 2008 FY | 173.05 Million USD | -1.61% |
| 2008 Q4 | 173.05 Million USD | -16.09% |
| 2008 Q1 | 196.83 Million USD | 11.91% |
| 2008 Q3 | 206.23 Million USD | -0.31% |
| 2007 Q2 | 178.49 Million USD | 0.45% |
| 2007 Q4 | 175.88 Million USD | -7.97% |
| 2007 Q3 | 191.12 Million USD | 7.08% |
| 2007 Q1 | 177.68 Million USD | 5.49% |
| 2007 FY | 175.88 Million USD | 4.42% |
| 2006 Q1 | 146.37 Million USD | 11.27% |
| 2006 Q3 | 177.29 Million USD | 9.55% |
| 2006 Q4 | 168.43 Million USD | -4.99% |
| 2006 FY | 168.43 Million USD | 28.04% |
| 2006 Q2 | 161.84 Million USD | 10.57% |
| 2005 Q2 | 140.48 Million USD | -5.17% |
| 2005 Q4 | 131.55 Million USD | -6.68% |
| 2005 FY | 131.55 Million USD | -5.97% |
| 2005 Q1 | 148.14 Million USD | 5.89% |
| 2005 Q3 | 140.96 Million USD | 0.34% |
| 2004 Q2 | 132.78 Million USD | 0.29% |
| 2004 Q3 | 140.96 Million USD | 6.16% |
| 2004 Q1 | 132.4 Million USD | 2.79% |
| 2004 FY | 139.9 Million USD | 8.61% |
| 2004 Q4 | 139.9 Million USD | -0.75% |
| 2003 Q3 | 126.15 Million USD | 2.62% |
| 2003 Q1 | 124.85 Million USD | 11.92% |
| 2003 FY | 128.81 Million USD | 15.47% |
| 2003 Q4 | 128.81 Million USD | 2.11% |
| 2003 Q2 | 122.93 Million USD | -1.54% |
| 2002 FY | 111.55 Million USD | 8.61% |
| 2002 Q4 | 111.55 Million USD | -10.97% |
| 2002 Q3 | 125.3 Million USD | 4.99% |
| 2002 Q2 | 119.34 Million USD | 8.76% |
| 2002 Q1 | 109.73 Million USD | 6.83% |
| 2001 Q4 | 102.71 Million USD | -10.71% |
| 2001 FY | 102.71 Million USD | 17.69% |
| 2001 Q2 | 107.47 Million USD | 11.71% |
| 2001 Q1 | 96.21 Million USD | 10.24% |
| 2001 Q3 | 115.04 Million USD | 7.04% |
| 2000 FY | 87.27 Million USD | 8.55% |
| 2000 Q1 | 87.3 Million USD | 8.59% |
| 2000 Q2 | 82.97 Million USD | -4.96% |
| 2000 Q3 | 86.09 Million USD | 3.75% |
| 2000 Q4 | 87.27 Million USD | 1.37% |
| 1999 Q4 | 80.4 Million USD | -7.27% |
| 1999 FY | 80.4 Million USD | 0.12% |
| 1999 Q1 | 77.5 Million USD | -3.49% |
| 1999 Q2 | 80.2 Million USD | 3.48% |
| 1999 Q3 | 86.7 Million USD | 8.1% |
| 1998 Q1 | 79.5 Million USD | -9.04% |
| 1998 FY | 80.3 Million USD | -8.12% |
| 1998 Q2 | 81.5 Million USD | 2.52% |
| 1998 Q3 | 82.9 Million USD | 1.72% |
| 1998 Q4 | 80.3 Million USD | -3.14% |
| 1997 Q2 | 49.3 Million USD | 0.82% |
| 1997 Q3 | 105.6 Million USD | 114.2% |
| 1997 Q4 | 87.4 Million USD | -17.23% |
| 1997 FY | 87.4 Million USD | 84.39% |
| 1997 Q1 | 48.9 Million USD | 3.16% |
| 1996 FY | 47.4 Million USD | 14.22% |
| 1996 Q1 | 40.4 Million USD | -2.65% |
| 1996 Q2 | 53.3 Million USD | 31.93% |
| 1996 Q4 | 47.4 Million USD | -7.96% |
| 1996 Q3 | 51.5 Million USD | -3.38% |
| 1995 Q1 | 45.4 Million USD | 0.0% |
| 1995 Q4 | 41.5 Million USD | -9.59% |
| 1995 Q2 | 46.8 Million USD | 3.08% |
| 1995 FY | 41.5 Million USD | 0.0% |
| 1995 Q3 | 45.9 Million USD | -1.92% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| uniQure N.V. | 12.02 Million USD | -4193.38% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -2606.207% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | -764.775% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -5218.731% |
| bluebird bio, Inc. | 22.91 Million USD | -2152.437% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -18199.752% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | - USD | -Infinity% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 385.86 Million USD | -33.787% |
| Myriad Genetics, Inc. | 20.1 Million USD | -2468.338% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -1247.875% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | -566.903% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 93.795% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 89.854% |
| Biogen Inc. | 2.52 Billion USD | 79.574% |
| Nektar Therapeutics | 16.1 Million USD | -3106.236% |
| Perrigo Company plc | 1.14 Billion USD | 54.752% |
| Dynavax Technologies Corporation | 53.29 Million USD | -868.73% |
| Illumina, Inc. | 587 Million USD | 12.055% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -4877.208% |
| Heron Therapeutics, Inc. | 42.11 Million USD | -1125.923% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 53.374% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -4593.908% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 79.995% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | -686.669% |
| FibroGen, Inc. | 41.56 Million USD | -1141.997% |
| Agilent Technologies, Inc. | 1.03 Billion USD | 49.929% |
| OPKO Health, Inc. | 65.69 Million USD | -685.783% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | -479.09% |
| Exelixis, Inc. | 17.32 Million USD | -2880.061% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 79.866% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -3310.875% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 21222.586% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 30.125% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -1716.134% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | -59.895% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -6578.344% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | -304.57% |
| Blueprint Medicines Corporation | 21.22 Million USD | -2332.437% |
| Insmed Incorporated | 83.24 Million USD | -520.118% |
| TG Therapeutics, Inc. | 39.82 Million USD | -1196.326% |
| Incyte Corporation | 62.97 Million USD | -719.787% |
| Emergent BioSolutions Inc. | 328.9 Million USD | -56.958% |